Breaking News Bar
updated: 6/19/2014 10:10 AM

Horizon secures $300 million finacing for Vidara acquisition

Success - Article sent! close

DEERFIELD -- Horizon Pharma has secured $300 million in financing to aid in its acquisition of Vidara Therapeutics International.

The financing agreement with a group of lenders will replace the $250 million bridge loan commitment received from Deerfield Management Company, L.P., according to Horizon. The company intends to use proceeds to complete the acquisition of Vidara, pay related transaction fees and expenses and for general corporate purposes.

Order Reprint Print Article
Interested in reusing this article?
Custom reprints are a powerful and strategic way to share your article with customers, employees and prospects.
The YGS Group provides digital and printed reprint services for Daily Herald. Complete the form to the right and a reprint consultant will contact you to discuss how you can reuse this article.
Need more information about reprints? Visit our Reprints Section for more details.

Contact information ( * required )

Success - request sent close

Citigroup Global Markets Inc. and Cowen and Company, LLC and their respective affiliates are acting as joint lead arrangers and initial lenders to Horizon for the financing.

Horizon announced earlier this year it will acquire Ireland-based Vidara for about $660 million. The new company will be named Horizon Pharma plc and be organized under the laws of Ireland with a portfolio of four products marketed primarily in the United States.

Vidara has operations in both Dublin and the United States. Its Actimmune drug, which it bought from InterMune Inc. in 2012 for $55 million, made nearly $59 million in sales for Vidara last year.

Share this page
Comments ()
Guidelines: Keep it civil and on topic; no profanity, vulgarity, slurs or personal attacks. People who harass others or joke about tragedies will be blocked. If a comment violates these standards or our terms of service, click the X in the upper right corner of the comment box. To find our more, read our FAQ.